Welcome to the XX iwCLL 2023 Call for Abstracts Submission Site

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) seeks original papers that address scientific questions, demonstrate new research/developments, or contain original scientific results related to the treatment of patients with chronic lymphocytic leukemia (CLL).

SUBMISSION DEADLINES
Submissions are editable until the May 31, 2023 submission deadline. Late-breaker submissions are editable from their opening on July 17, 2023 until their submission deadline of August 11, 2023. Please refer to the list of deadlines below:

February 1, 2023 – YIM & iwCLL Call for Abstracts
May 31, 2023 – YIM & iwCLL Abstract Submission Deadline
July 14, 2023 – YIM & iwCLL Abstract Notifications
July 17, 2023 – General Abstract Late-Breakers Open
August 1, 2023 – Abstract Withdrawal Deadline
August 11, 2023 – General Abstract Late-Breakers Closed
September 18, 2023 – Late-Breakers Notifications (rolling basis)

Any questions regarding abstract submissions should be sent to iwcll@bioascend.com

SUBMISSION REQUIREMENTS
Before beginning your abstract submission, you will be asked to create an account. You will also be required to create an access key that you will use to access your submission information in the future.

The abstract submission process consists of the following tasks: author profile information, abstract information, additional information (Encore and Trials in Progress abstract types only), uploads, and attestation.

Submitters will be able to save a draft and return to complete the submission. Completed submissions will also be editable before the May 31 deadline date when you log back into the abstract submission system.

IMPORTANT: You will be asked to submit your abstract in text box form as well as upload a Word file of your abstract (.doc, .docx). The presenting author and coauthor details should be excluded from both.

AUTHOR PROFILE INFORMATION - The presenting author must provide complete contact information (full name, degree, institution, address, telephone number, and email address) in the abstract submission system. A profile image and biographical sketch are optional. The presenting author will receive all correspondence from iwCLL regarding the status of the abstract and instructions regarding presentation and publishing. Presenting authors must also provide coauthor information on the author profile page of the abstract submission system.

ABSTRACT INFORMATION - the following are mandatory:

• ABSTRACT TITLE
• 300-character limit, including spaces
• Not counted toward total word count
• ABSTRACT TYPE
• General:  All types of clinical-based and laboratory-based research projects relating to CLL and B-cell lymphoproliferative disorders
• Encore: Abstracts containing updated data with respect to a previous presentation. Authors must supply information regarding the original presentation for identification and comparison purposes, indicating the name of the meeting, year, and/or publication number. Encores will not be accepted if published or presented prior to April 6, 2023.
• Trials in Progress (TiP): Must provide if the trial has been registered, the registry, and the registration number
• Late-Breaking General: General Abstract Types accepted during the late-breaking submission window of July 17-August 11, 2023
• CATEGORY
• Laboratory-based research
• Clinical-based research
• Real-world evidence
• TOPIC
• Pathogenesis of CLL
• Integrative Aspects of Genomics
• Proteomics and Metabolism of CLL
• Microenvironment and Pre-Clinical Immunotherapies
• Debate and Roundtable - How Do We Define Success in CLL
• Therapy of CLL
• Optimizing Initial Therapy of CLL
• Clinical Challenges in CLL
• Mechanisms of Resistance
• Refractory CLL - Mechanisms and Treatment
• Richter's Transformation - From Biology to Clinic
• Natural History and Supportive Care of CLL in the Era of COVID-19
• Global Perspective on CLL Management - Real World Data and Patient Experiences
• Past, Present, and Future in CLL
• Natural History and Supportive Care of CLL in the Era of COVID-19
• Global Perspective on CLL Management - Real World Data and Patient Experiences
• Past, Present, and Future in CLL
• ADDITIONAL QUESTIONS
• Which meeting the abstract submission is intended for (YIM, iwCLL Main Meeting, or both YIM & iwCLL Main Meeting)
• If submitting from an Official Development Assistance (ODA)-eligible country
• ABSTRACT TEXT
• Paste your abstract text; exclude author information; 700-word limited (headers included in word count); structure permitted; references cited within text; must be in English
• KEYWORDS
• Limit to 3 (leukemia, relapsed/refractory, biomarker, etc.)

ADDITIONAL INFORMATION- the following are required for Encore and TiP Abstract Types:

• Encore
• Selected as an oral, a poster, or published only
• Name and date of meeting where project was presented
• TiP
• Registered status
• Registry type
• Registration #
• Patient accrual

UPLOADS

• ABSTRACT UPLOAD
• Exclude all author information
• Microsoft Word (.doc or .docx)
• 700-word limit (headers included in word count)
• Structure is permitted, but not required (Introduction, Methods, Results, and Conclusions)
• Multiple paragraphs are permitted
• 2 tables/figures/graphs/images may be included
• References are to be cited within the text, not as footnotes
• Abstracts must be in English
• ADDITIONAL FILE UPLOADS
• May include two (2) tables, figures, graphs, or images
• Maximum file size: 10 MB
• File types limited to .jpeg, .png, .pdf

ATTESTATION - Complete the agreement and sign electronically